Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty

Edouard Cheneau, Seung-Woon Rha, Pramod K. Kuchulakanti, Eugenio Stabile, Timothy Kinnaird, Rebecca Torguson, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Ron Waksman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Sirolimus-eluting stents (SESs) are currently being used in patients undergoing percutaneous coronary intervention (PCI). SESs have not been evaluated in the treatment of acute myocardial infarction by primary angioplasty. We report our initial experience with SESs implanted during primary angioplasty. One hundred and three patients were treated within 12 hr after onset of acute myocardial infarction (AMI) with primary angioplasty and SES implantation. Those patients were compared to 504 patients treated with bare metal stents (BMSs). Angiographic success (TIMI flow grade 3 and residual stenosis < 50%) was completed in 98% of patients with SESs and no subacute stent thrombosis was reported. Inhospital outcomes were similar in the SES and BMS groups. At 6 months, major cardiac events were less frequent in the SES group than in the BMS group (9% vs. 24%, respectively; P < 0.001), driven by a lesser need for repeat revascularization with SESs (1% vs. 10.3% with BMSs; P = 0.014). Mortality at 6 months was 7% with SESs and 11% with BMSs (P = 0.14). SESs are safe and effective for the treatment of AMI by primary angioplasty. As compared to BMSs, SESs improve long-term outcome after AMI, mainly by reducing the need for repeat revascularization.

Original languageEnglish
Pages (from-to)469-472
Number of pages4
JournalCatheterization and Cardiovascular Interventions
Volume65
Issue number4
DOIs
Publication statusPublished - 2005 Aug 1
Externally publishedYes

Fingerprint

Sirolimus
Angioplasty
Stents
Myocardial Infarction
Metals
Percutaneous Coronary Intervention

Keywords

  • Drug-eluting stent
  • Myocardial infarction
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. / Cheneau, Edouard; Rha, Seung-Woon; Kuchulakanti, Pramod K.; Stabile, Eugenio; Kinnaird, Timothy; Torguson, Rebecca; Pichard, Augusto D.; Satler, Lowell F.; Kent, Kenneth M.; Waksman, Ron.

In: Catheterization and Cardiovascular Interventions, Vol. 65, No. 4, 01.08.2005, p. 469-472.

Research output: Contribution to journalArticle

Cheneau, E, Rha, S-W, Kuchulakanti, PK, Stabile, E, Kinnaird, T, Torguson, R, Pichard, AD, Satler, LF, Kent, KM & Waksman, R 2005, 'Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty', Catheterization and Cardiovascular Interventions, vol. 65, no. 4, pp. 469-472. https://doi.org/10.1002/ccd.20395
Cheneau, Edouard ; Rha, Seung-Woon ; Kuchulakanti, Pramod K. ; Stabile, Eugenio ; Kinnaird, Timothy ; Torguson, Rebecca ; Pichard, Augusto D. ; Satler, Lowell F. ; Kent, Kenneth M. ; Waksman, Ron. / Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. In: Catheterization and Cardiovascular Interventions. 2005 ; Vol. 65, No. 4. pp. 469-472.
@article{03e3b57a14bd421b97a2108c3df840f3,
title = "Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty",
abstract = "Sirolimus-eluting stents (SESs) are currently being used in patients undergoing percutaneous coronary intervention (PCI). SESs have not been evaluated in the treatment of acute myocardial infarction by primary angioplasty. We report our initial experience with SESs implanted during primary angioplasty. One hundred and three patients were treated within 12 hr after onset of acute myocardial infarction (AMI) with primary angioplasty and SES implantation. Those patients were compared to 504 patients treated with bare metal stents (BMSs). Angiographic success (TIMI flow grade 3 and residual stenosis < 50{\%}) was completed in 98{\%} of patients with SESs and no subacute stent thrombosis was reported. Inhospital outcomes were similar in the SES and BMS groups. At 6 months, major cardiac events were less frequent in the SES group than in the BMS group (9{\%} vs. 24{\%}, respectively; P < 0.001), driven by a lesser need for repeat revascularization with SESs (1{\%} vs. 10.3{\%} with BMSs; P = 0.014). Mortality at 6 months was 7{\%} with SESs and 11{\%} with BMSs (P = 0.14). SESs are safe and effective for the treatment of AMI by primary angioplasty. As compared to BMSs, SESs improve long-term outcome after AMI, mainly by reducing the need for repeat revascularization.",
keywords = "Drug-eluting stent, Myocardial infarction, Percutaneous coronary intervention",
author = "Edouard Cheneau and Seung-Woon Rha and Kuchulakanti, {Pramod K.} and Eugenio Stabile and Timothy Kinnaird and Rebecca Torguson and Pichard, {Augusto D.} and Satler, {Lowell F.} and Kent, {Kenneth M.} and Ron Waksman",
year = "2005",
month = "8",
day = "1",
doi = "10.1002/ccd.20395",
language = "English",
volume = "65",
pages = "469--472",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty

AU - Cheneau, Edouard

AU - Rha, Seung-Woon

AU - Kuchulakanti, Pramod K.

AU - Stabile, Eugenio

AU - Kinnaird, Timothy

AU - Torguson, Rebecca

AU - Pichard, Augusto D.

AU - Satler, Lowell F.

AU - Kent, Kenneth M.

AU - Waksman, Ron

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Sirolimus-eluting stents (SESs) are currently being used in patients undergoing percutaneous coronary intervention (PCI). SESs have not been evaluated in the treatment of acute myocardial infarction by primary angioplasty. We report our initial experience with SESs implanted during primary angioplasty. One hundred and three patients were treated within 12 hr after onset of acute myocardial infarction (AMI) with primary angioplasty and SES implantation. Those patients were compared to 504 patients treated with bare metal stents (BMSs). Angiographic success (TIMI flow grade 3 and residual stenosis < 50%) was completed in 98% of patients with SESs and no subacute stent thrombosis was reported. Inhospital outcomes were similar in the SES and BMS groups. At 6 months, major cardiac events were less frequent in the SES group than in the BMS group (9% vs. 24%, respectively; P < 0.001), driven by a lesser need for repeat revascularization with SESs (1% vs. 10.3% with BMSs; P = 0.014). Mortality at 6 months was 7% with SESs and 11% with BMSs (P = 0.14). SESs are safe and effective for the treatment of AMI by primary angioplasty. As compared to BMSs, SESs improve long-term outcome after AMI, mainly by reducing the need for repeat revascularization.

AB - Sirolimus-eluting stents (SESs) are currently being used in patients undergoing percutaneous coronary intervention (PCI). SESs have not been evaluated in the treatment of acute myocardial infarction by primary angioplasty. We report our initial experience with SESs implanted during primary angioplasty. One hundred and three patients were treated within 12 hr after onset of acute myocardial infarction (AMI) with primary angioplasty and SES implantation. Those patients were compared to 504 patients treated with bare metal stents (BMSs). Angiographic success (TIMI flow grade 3 and residual stenosis < 50%) was completed in 98% of patients with SESs and no subacute stent thrombosis was reported. Inhospital outcomes were similar in the SES and BMS groups. At 6 months, major cardiac events were less frequent in the SES group than in the BMS group (9% vs. 24%, respectively; P < 0.001), driven by a lesser need for repeat revascularization with SESs (1% vs. 10.3% with BMSs; P = 0.014). Mortality at 6 months was 7% with SESs and 11% with BMSs (P = 0.14). SESs are safe and effective for the treatment of AMI by primary angioplasty. As compared to BMSs, SESs improve long-term outcome after AMI, mainly by reducing the need for repeat revascularization.

KW - Drug-eluting stent

KW - Myocardial infarction

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=23044471223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044471223&partnerID=8YFLogxK

U2 - 10.1002/ccd.20395

DO - 10.1002/ccd.20395

M3 - Article

C2 - 15988741

AN - SCOPUS:23044471223

VL - 65

SP - 469

EP - 472

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 4

ER -